It turned out they hadn't even begun US FDA trials and were going to Europe first with CE Mark approval. The most drastic contrast between RPC and BMOD is RPC racked up some insane amount of debt developing their test which has not even begun funding any type of FDA trials yet. They just converted all this debt into shares and diluted their shareholders into the ground. Now they still need to pay for Pilot Study/Phase II and Pivotal Trial/Phase III.
Contrast this to BMOD who scraped and scrapped on a shoe string budget the whole way.....who pulled off an amazing move when they were able to get New Mexico to fund Phase II trials. BMOD carrying virtually no debt, less than 100m shares O/S and on the verge of releasing the long awaited test results. Test results which our new CEO told us are good enough to move us along to Phase III Pivotal Trial.
Market Data 
Markets 
AI
